Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 336

1.

Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial.

Wanner C, Heerspink HJL, Zinman B, Inzucchi SE, Koitka-Weber A, Mattheus M, Hantel S, Woerle HJ, Broedl UC, von Eynatten M, Groop PH; EMPA-REG OUTCOME Investigators.

J Am Soc Nephrol. 2018 Oct 12. pii: ASN.2018010103. doi: 10.1681/ASN.2018010103. [Epub ahead of print]

PMID:
30314978
2.

Single dose of empagliflozin increases in vivo cardiac energy status in diabetic db/db mice.

Abdurrachim D, Manders E, Nicolay K, Mayoux E, Prompers JJ.

Cardiovasc Res. 2018 Oct 5. doi: 10.1093/cvr/cvy246. [Epub ahead of print] No abstract available.

PMID:
30295756
3.

Empagliflozin Ammeliorates High Glucose Induced-Cardiac Dysfuntion in Human iPSC-Derived Cardiomyocytes.

Ng KM, Lau YM, Dhandhania V, Cai ZJ, Lee YK, Lai WH, Tse HF, Siu CW.

Sci Rep. 2018 Oct 5;8(1):14872. doi: 10.1038/s41598-018-33293-2.

4.

Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials.

Rosenstock J, Marquard J, Laffel LM, Neubacher D, Kaspers S, Cherney DZ, Zinman B, Skyler JS, George J, Soleymanlou N, Perkins BA.

Diabetes Care. 2018 Oct 4. pii: dc181749. doi: 10.2337/dc18-1749. [Epub ahead of print]

PMID:
30287422
5.

Empagliflozin improves cardiorespiratory fitness in type 2 diabetes: Translational implications.

Kumar N, Garg A, Bhatt DL, Sabongui S, Gupta N, Chaudhry S, Arena R, Verma S.

Can J Physiol Pharmacol. 2018 Sep 28. doi: 10.1139/cjpp-2018-0359. [Epub ahead of print]

PMID:
30265814
6.

Precision medicine approach: Empagliflozin for diabetic cardiomyopathy in mice with aldehyde dehydrogenase (ALDH) 2 * 2 mutation, a specific genetic mutation in millions of East Asians.

Pan G, Deshpande M, Pang H, Palaniyandi SS.

Eur J Pharmacol. 2018 Sep 19;839:76-81. doi: 10.1016/j.ejphar.2018.09.021. [Epub ahead of print]

PMID:
30240795
7.

Empagliflozin lowers myocardial ketone utilization while preserving glucose utilization in diabetic hypertensive heart disease: A hyperpolarized 13 C magnetic resonance spectroscopy study.

Abdurrachim D, Teo XQ, Woo CC, Chan WX, Lalic J, Lam CSP, Lee PTH.

Diabetes Obes Metab. 2018 Sep 17. doi: 10.1111/dom.13536. [Epub ahead of print]

PMID:
30225964
8.

Efficacy of intermittent empagliflozin supplementation on dietary self-management and glycaemic control in patients with poorly controlled type 2 diabetes: A 24-week randomized controlled trial.

Yoshikawa F, Kumashiro N, Shigiyama F, Uchino H, Ando Y, Yoshino H, Miyagi M, Ikehara K, Hirose T.

Diabetes Obes Metab. 2018 Sep 5. doi: 10.1111/dom.13524. [Epub ahead of print]

PMID:
30187632
9.

Resistance to Diuretics in Heart Failure: Any Role for Empagliflozin?

Katsiki N, Triposkiadis F.

Curr Vasc Pharmacol. 2018 Aug 31. doi: 10.2174/1570161116666180831124717. [Epub ahead of print] No abstract available.

PMID:
30173648
10.

The Favorable Effect of Empagliflozin on Erectile Function in an Experimental Model of Type 2 Diabetes.

Assaly R, Gorny D, Compagnie S, Mayoux E, Bernabe J, Alexandre L, Giuliano F, Behr-Roussel D.

J Sex Med. 2018 Sep;15(9):1224-1234. doi: 10.1016/j.jsxm.2018.07.002. Epub 2018 Aug 23.

PMID:
30145094
11.

Real-world opportunity of empagliflozin to improve blood pressure control in African American patients with type 2 diabetes: A National Cardiovascular Data Registry "research-to-practice" project from the diabetes collaborative registry.

Arnold SV, Seman L, Tang F, Peri-Okonny PA, Ferdinand KC, Mehta SN, Goyal A, Sperling LS, Kosiborod M.

Diabetes Obes Metab. 2018 Aug 23. doi: 10.1111/dom.13510. [Epub ahead of print]

PMID:
30136353
12.

Empagliflozin reduces Ca/calmodulin-dependent kinase II activity in isolated ventricular cardiomyocytes.

Mustroph J, Wagemann O, Lücht CM, Trum M, Hammer KP, Sag CM, Lebek S, Tarnowski D, Reinders J, Perbellini F, Terracciano C, Schmid C, Schopka S, Hilker M, Zausig Y, Pabel S, Sossalla ST, Schweda F, Maier LS, Wagner S.

ESC Heart Fail. 2018 Aug;5(4):642-648. doi: 10.1002/ehf2.12336.

13.

Safety and tolerability of empagliflozin in East Asian patients with type 2 diabetes: Pooled analysis of phase I-III clinical trials.

Yabe D, Yasui A, Ji L, Lee MK, Ma RCW, Chang TJ, Okamura T, Zeller C, Kaspers S, Lee J, Kohler S, Seino Y.

J Diabetes Investig. 2018 Aug 12. doi: 10.1111/jdi.12910. [Epub ahead of print]

14.

Effect of Empagliflozin Versus Placebo on Cardiac Sympathetic Activity in Acute Myocardial Infarction Patients with Type 2 Diabetes Mellitus: Rationale.

Kubota Y, Yamamoto T, Tara S, Tokita Y, Yodogawa K, Iwasaki Y, Takano H, Tsukada Y, Asai K, Miyamoto M, Miyauchi Y, Kodani E, Sato N, Tanabe J, Shimizu W.

Diabetes Ther. 2018 Oct;9(5):2107-2116. doi: 10.1007/s13300-018-0480-7. Epub 2018 Aug 10.

15.

Linagliptin as add-on to empagliflozin in a fixed-dose combination in Japanese patients with type 2 diabetes: Glycaemic efficacy and safety profile in a two-part, randomized, placebo-controlled trial.

Kaku K, Haneda M, Tanaka Y, Lee G, Shiki K, Miyamoto Y, Solimando F, Lee J, Lee C, George J.

Diabetes Obes Metab. 2018 Aug 9. doi: 10.1111/dom.13496. [Epub ahead of print]

PMID:
30091172
16.

Empagliflozin, SGLT2 inhibitor, attenuates renal fibrosis in rats exposed to unilateral ureteric obstruction: potential role of klotho expression.

Abbas NAT, El Salem A, Awad MM.

Naunyn Schmiedebergs Arch Pharmacol. 2018 Aug 8. doi: 10.1007/s00210-018-1544-y. [Epub ahead of print]

PMID:
30090949
17.

Usefulness of Empagliflozin Versus Liraglutide for Prevention of Cardiovascular Mortality.

Arbel R, Hammerman A, Azuri J.

Am J Cardiol. 2018 Sep 15;122(6):981-984. doi: 10.1016/j.amjcard.2018.06.010. Epub 2018 Jun 22.

PMID:
30075890
18.

The safety of empagliflozin plus metformin for the treatment of type 2 diabetes.

Scheen AJ.

Expert Opin Drug Saf. 2018 Aug;17(8):837-848. doi: 10.1080/14740338.2018.1497159. Epub 2018 Aug 1. Review.

PMID:
30068236
19.

Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME® trial.

Sattar N, Fitchett D, Hantel S, George JT, Zinman B.

Diabetologia. 2018 Oct;61(10):2155-2163. doi: 10.1007/s00125-018-4702-3. Epub 2018 Jul 31.

20.

Empagliflozin and the Prevention of Heart Failure: Will Reverse Translation Lead to New Paradigms for the Treatment of Heart Failure?

Mann DL, Kelly DP.

JACC Basic Transl Sci. 2017 Aug 4;2(4):355-357. doi: 10.1016/j.jacbts.2017.07.004. eCollection 2017 Aug. No abstract available.

Supplemental Content

Loading ...
Support Center